Marshall Fordyce Sells 14,471 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96. Following the transaction, the chief executive officer now directly owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vera Therapeutics Price Performance

NASDAQ:VERA traded up $0.18 during mid-day trading on Friday, hitting $39.30. The company’s stock had a trading volume of 301,331 shares, compared to its average volume of 962,849. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -19.12 and a beta of 0.99. The stock has a fifty day moving average of $36.24 and a 200-day moving average of $39.94. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a fifty-two week low of $9.24 and a fifty-two week high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of Vera Therapeutics

Hedge funds have recently modified their holdings of the company. Public Employees Retirement Association of Colorado bought a new stake in shares of Vera Therapeutics during the second quarter valued at approximately $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics during the second quarter valued at approximately $163,000. Ameritas Investment Partners Inc. grew its stake in shares of Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares during the last quarter. Cetera Advisors LLC bought a new stake in shares of Vera Therapeutics during the first quarter valued at approximately $235,000. Finally, Quarry LP bought a new stake in shares of Vera Therapeutics during the second quarter valued at approximately $235,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Raymond James increased their price target on shares of Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. JPMorgan Chase & Co. dropped their price target on shares of Vera Therapeutics from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $42.43.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.